A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Albert Gris‐Oliver et al.|EMBO Molecular Medicine|2018Cited by 271
TAK1 Suppresses a NEMO-Dependent but NF-κB-Independent Pathway to Liver CancerKira Bettermann, Tom Luedde, Mihael Vucur et al.|Cancer Cell|2010Cited by 220
Correlation Revealed between Gemtuzumab-Ozogamicin Efficacy and CD33+ Expression in AML Primary Samples through a Novel AML in Vitro ModelMara Gilardi, Michael Ritchie, Garima Kaushik et al.|Blood|2023Cited by 1